Cost-effectiveness of elbasvir/grazoprevir plus sofosbuvir for the treatment of chronic HCV genotype 3 infection in Argentina

被引：0
|
作者：
Bissio, E. [1 ]
Nwankwo, C. [2 ]
Corman, S. [3 ]
Monsanto, H. [4 ]
Montes, J. L. [1 ]
机构：
[1] MSD Argentina, Med Affairs, Munro, Argentina
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Pharmerit Int, Bethesda, MD USA
[4] Merck Sharp & Dohme IA LLC, Latin Amer Hlth Outcomes Res, Carolina, PR USA
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30591-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-138
引用
收藏
页码：S189 / S190
页数：2
相关论文
共 50 条
  • [1] Grazoprevir/Elbasvir plus Sofosbuvir in HCV Genotype 1, 4 Infection after failure of sofosbuvir-based therapy
    Ajlan, Aziza A.
    Ahmed, Mohamed
    Abu-Riash, Tamadhor
    Aljedai, Ahmed
    HEPATOLOGY, 2017, 66 : 861A - 861A
  • [2] Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
    Liu, Jinyu
    Guo, Min
    Ke, Lei
    You, Ruxu
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [3] Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report
    Tadokoro, Tomoko
    Morishita, Asahiro
    Oura, Kyoko
    Fujita, Koji
    Mimura, Shima
    Sakamoto, Teppei
    Nomura, Takako
    Tani, Joji
    Yoneyama, Hirohito
    Masaki, Tsutomu
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 16 (02) : 1026 - 1028
  • [4] Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China
    Chen, Pingyu
    Ma, Aixia
    Liu, Qiang
    CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1031 - 1039
  • [5] COST-EFFECTIVENESS OF GRAZOPREVIR / ELBASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS
    Mattingly, T. J., III
    Slejko, J. F.
    Mullins, C. D.
    VALUE IN HEALTH, 2016, 19 (07) : A415 - A415
  • [6] Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China
    Pingyu Chen
    Aixia Ma
    Qiang Liu
    Clinical Drug Investigation, 2018, 38 : 1031 - 1039
  • [7] ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS OF TREATMENT WITH DACLATASVIR plus SOFOSBUVIR IN PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 3
    McEwan, P.
    Ward, T.
    Webster, S.
    Kalsekar, A.
    Brenner, M.
    Yuan, Y.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S666 - S667
  • [8] ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS OF TREATMENT WITH DACLATASVIR plus SOFOSBUVIR IN PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 3
    McEwan, P.
    Ward, T.
    Webster, S.
    Kalsekar, A.
    Brenner, M.
    Yuan, Y.
    VALUE IN HEALTH, 2015, 18 (03) : A240 - A240
  • [9] Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection
    Saab, S.
    Gordon, S. C.
    Park, H.
    Sulkowski, M.
    Ahmed, A.
    Younossi, Z.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (06) : 657 - 675
  • [10] EFFECTIVENESS OF SOFOSBUVIR/VELPATASVIR AND ELBASVIR/GRAZOPREVIR FOR THE TREATMENT OF HCV GENOTYPE 1 INFECTION IN A REAL-WORLD COHORT WITH NUMEROUS PEOPLE WHO USE DRUGS (PWUD)
    Wuerth, Kelli
    Magel, Tianna
    Thiam, Astou
    Alimohammadi, Arshia
    Yung, Rossitta
    Truong, David
    Conway, Brian
    HEPATOLOGY, 2019, 70 : 959A - 959A
12345